# AstraZeneca vs Novartis: stocks compared

URL: https://funkfolio.com/compare/azn-vs-nvs

> AstraZeneca ($282.7B, P/E 26.0) and Novartis ($300.5B, P/E 30.6) compared: size, valuation, margins, debt, cash and price change.

---

## AstraZeneca vs Novartis

AstraZeneca (AZN), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Novartis is worth $300.5B on the stock market and AstraZeneca $282.7B: Novartis is valued at 6% more. AstraZeneca trades at 26.0 times earnings and Novartis at 30.6; operating margins in their latest fiscal years were 23.4% and 32.4%. Over the past year AstraZeneca's share price has moved +2.75% and Novartis's +25.1%.

### Key facts

- **AstraZeneca market value:** $282.7B
- **Novartis market value:** $300.5B
- **AstraZeneca P/E:** 26.0
- **Novartis P/E:** 30.6
- **AstraZeneca revenue:** $58.7B FY to 2025-12-31
- **Novartis revenue:** $54.5B FY to 2025-12-31
- **Superinvestors holding both:** 7

Market values as of 18 Nov 2026, 04:50 UTC.

AstraZeneca vs Novartis: every measure side by side

| Measure | AstraZeneca | Novartis |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United Kingdom | Switzerland |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $282.7B lower | $300.5B higher |
| Revenue | $58.7B higher | $54.5B lower |
| Earnings | $10.2B lower | $14B higher |
| Employees | 96,100 higher | 75,267 lower |
| Total assets | $114.1B higher | $110.9B lower |
| Valuation |  |  |
| P/E | 26.0 lower | 30.6 higher |
| P/S | 4.8 lower | 5.5 higher |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability |  |  |
| Operating margin | 23.4% lower | 32.4% higher |
| Balance sheet |  |  |
| Net assets | $48.7B higher | $46.1B lower |
| Total liabilities | $65.4B higher | $64.4B lower |
| Total debt | $29.6B higher | $28.7B lower |
| Cash on hand | $5.7B lower | $11.4B higher |
| Price change |  |  |
| Today | -0.95% lower | -0.67% higher |
| 1 year | +2.75% lower | +25.1% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: AstraZeneca 101.9, Novartis 121.0.

- AstraZeneca (AZN)
- Novartis (NVS)

AstraZeneca and Novartis share prices over one year, rebased to 100: AstraZeneca ends at 101.9, Novartis at 121.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | AZN | NVS |
| --- | --- | --- |
| Nov 28, 2025 | 103.7 | 99.1 |
| Dec 31, 2025 | 102.8 | 104.8 |
| Jan 30, 2026 | 103.8 | 113.0 |
| Feb 27, 2026 | 116.6 | 128.2 |
| Mar 31, 2026 | 110.3 | 116.1 |
| Apr 30, 2026 | 104.8 | 112.4 |
| May 29, 2026 | 103.8 | 114.2 |
| Jun 30, 2026 | 106.1 | 119.1 |
| Jul 31, 2026 | 94.9 | 118.7 |
| Aug 31, 2026 | 90.7 | 115.6 |
| Sep 30, 2026 | 90.3 | 108.4 |
| Oct 30, 2026 | 104.4 | 122.2 |
| Nov 17, 2026 | 101.9 | 121.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (7)

- [Primecap team](https://funkfolio.com/gurus/primecap) 1.8% / 0.6%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 1.1% / 0.4%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.7% / 0.3%
- [Ken Fisher](https://funkfolio.com/gurus/ken-fisher) 0.5% / 0.7%
- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 0.4% / 0.2%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) &lt;0.1% / 0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1% / &lt;0.1%

#### AstraZeneca only (5)

- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 20.2%
- [Lew Sanders](https://funkfolio.com/gurus/lew-sanders) 1.1%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.4%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Polen Capital team](https://funkfolio.com/gurus/polen-capital) &lt;0.1%

#### Novartis only (6)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.8%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 0.3%
- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.2%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.1%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) &lt;0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": AstraZeneca / Novartis). [Who owns AZN](https://funkfolio.com/stock/AZN/superinvestors) · [Who owns NVS](https://funkfolio.com/stock/NVS/superinvestors)

### More on AstraZeneca

- [AstraZeneca (AZN) stock page](https://funkfolio.com/stock/AZN)
- [AstraZeneca market cap](https://funkfolio.com/stock/AZN/market-cap)
- [AstraZeneca revenue](https://funkfolio.com/stock/AZN/revenue)
- [AstraZeneca P/E ratio](https://funkfolio.com/stock/AZN/pe-ratio)
- [AstraZeneca operating margin](https://funkfolio.com/stock/AZN/operating-margin)
- [AstraZeneca total debt](https://funkfolio.com/stock/AZN/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Novartis

- [Novartis (NVS) stock page](https://funkfolio.com/stock/NVS)
- [Novartis market cap](https://funkfolio.com/stock/NVS/market-cap)
- [Novartis revenue](https://funkfolio.com/stock/NVS/revenue)
- [Novartis P/E ratio](https://funkfolio.com/stock/NVS/pe-ratio)
- [Novartis operating margin](https://funkfolio.com/stock/NVS/operating-margin)
- [Novartis total debt](https://funkfolio.com/stock/NVS/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### AstraZeneca against its closest peers

- [AstraZeneca vs UnitedHealth Group](https://funkfolio.com/compare/azn-vs-unh)
- [AstraZeneca vs Thermo Fisher Scientific](https://funkfolio.com/compare/azn-vs-tmo)
- [AstraZeneca vs Merck & Co](https://funkfolio.com/compare/azn-vs-mrk)

#### Novartis against its closest peers

- [Novartis vs UnitedHealth Group](https://funkfolio.com/compare/nvs-vs-unh)
- [Novartis vs Merck & Co](https://funkfolio.com/compare/mrk-vs-nvs)
- [Novartis vs Thermo Fisher Scientific](https://funkfolio.com/compare/nvs-vs-tmo)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, AstraZeneca or Novartis?**

By market value, Novartis is the larger: $300.5B against $282.7B for AstraZeneca. By revenue in its latest fiscal year, AstraZeneca is the larger: $58.7B against $54.5B for Novartis.

**Which has the higher P/E ratio?**

Novartis: 30.6, against 26.0 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Novartis: 32.4%, against 23.4% for AstraZeneca. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

AstraZeneca: $29.6B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both AstraZeneca and Novartis?**

In their latest 13F filings, Primecap team, Brandon Haley, Larry Robbins, Ken Fisher, Andrew Spokes, Dodge & Cox team and Rajiv Jain hold both.

### Cite this page

Funkfolio, “AstraZeneca vs Novartis”, data as of 18 November 2026. https://funkfolio.com/compare/azn-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
